Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg…
Profound Medical Corp. (PROF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (N
How this was made
The 30-second read
Why it matters
The preliminary revenue beat may trigger short‑term buying interest ahead of the full Q3 results scheduled for Nov 5.
Market read
First‑time disclosure of Q3‑2026 revenue guidance, materially above consensus, offering a fresh trading catalyst for PROF.
What to watch
Potential regulatory or reimbursement hurdles could temper revenue growth despite the guidance.
Profound Medical anticipates preliminary unaudited third quarter 2026 revenue of $9.8 million to $10.0 million and gross margin exceeding 70%.
The Company anticipates record quarterly revenue of $9.8 million to $10.0 million, approximately 85% to 89% above the third quarter of 2025 and approximately 292% to 300% above the second quarter of 2026, while expecting gross margin to again exceed 70%.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, third quarter 2026 (preliminary unaudited)other | $9.8 million to $10.0 million | approximately 292% to 300% | approximately 85% to 89% |
| Gross margin, Q3-2026 (expected)other | exceed 70% | – | – |
three months ended September 30, 2026 outlook
- Revenue$9.8 million to $10.0 million
- Gross marginexceed 70%
- NoteThe revenue and gross-margin figures are preliminary and unaudited, and actual revenues may differ.
What drove it
- The Company attributed expected year-over-year and sequential revenue growth to increased commercial activity across its installed base and new customer accounts.
- Management cited continued progress in commercial operations and scale as supporting expected gross margin above 70%.
- Management remains focused on supporting customer adoption and increasing utilization of its installed base.
Concerns
- The reported revenue and gross-margin figures are preliminary and unaudited, and actual revenues may differ.
- The Company stated that its financial outlook is based on assumptions and actual operating results may vary materially from the projections.
- No profitability, operating-expense, cash-flow, balance-sheet, or capital-return results were provided in this preliminary release.
What to watch
- Full third quarter 2026 financial results, which Profound intends to report after market close on Thursday, November 5th.
- Whether final reported revenue confirms the preliminary range of $9.8 million to $10.0 million.
- Final gross margin and the sustainability of commercial activity across the installed base and new customer accounts.
- Any disclosed operating expenses, profitability, liquidity, cash flow, and capital requirements in the full results.
Analysis
Profound issued a preliminary, unaudited third quarter 2026 revenue outlook rather than full financial results. The Company anticipates total revenue of $9.8 million to $10.0 million for the quarter ended September 30, 2026, compared with $5.3 million in the third quarter of 2025 and $2.5 million in the second quarter of 2026. It characterized this as approximately 85% to 89% year-over-year growth and approximately 292% to 300% sequential growth.
The expected revenue outcome points to a substantial acceleration in commercial activity relative to both comparison periods. Management attributed the expected growth to increased activity across the installed base and new customer accounts. The release did not provide product-level, geographic, customer, installed-base, procedure-volume, or segment revenue disclosures, so the respective contributions to the anticipated growth are not quantified.
Expected gross margin is again above 70%, which management said reflects continued progress in commercial operations and scale. That margin expectation is important alongside the anticipated revenue step-up because it indicates that the Company expects the higher revenue level to retain a gross-profit profile above that threshold. The release did not provide a prior-year gross margin, a prior-quarter gross margin, gross profit, operating expenses, operating income, net income, or earnings per share.
The preliminary figures are explicitly subject to change, with the Company stating that actual revenues may differ. Profound intends to report full third quarter 2026 financial results after market close on Thursday, November 5th. The full release will be needed to assess final revenue, gross-margin detail, operating leverage, cash flow, liquidity, and the financial requirements associated with the Company's stated focus on building a profitable growth company over the long term.
Management, verbatim
The significant increase in revenue we expect to report this quarter represents a historic milestone for Profound, reflecting the strong commercial momentum building behind our technology.
Arun Menawat, Profound’s CEO and Chairman
With preliminary revenue of approximately $9.8 million to $10.0 million and gross margin expected to exceed 70%, we believe the third quarter represents an important step in the continued expansion of our commercial business. We remain focused on supporting customer adoption, increasing utilization of our installed base, and building a profitable growth company over the long-term.
Arun Menawat, Profound’s CEO and Chairman
Not in the filing
stated, not guessed- Final reported third quarter 2026 revenue and final gross margin
- Revenue by product, geography, customer type, or operating segment
- Gross profit
- Prior-year and prior-quarter gross margin
- Operating expenses
- Operating income or loss
- Net income or loss
- GAAP and non-GAAP earnings per share
- GAAP and non-GAAP reconciliations
- Operating cash flow
- Free cash flow
- Cash, cash equivalents, and debt
- Share repurchases, dividends, or other capital returns
- Tax rate
- Forward guidance beyond the preliminary outlook for the three months ended September 30, 2026
- Prior company guidance for comparison
- Installed-base, procedure-volume, and new-customer-account metrics
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Profound Medical is a commercial‑stage medical‑device company focused on MRI‑guided prostate and pain‑palliation therapies.
Ticker impact
Profound Medical disclosed preliminary Q3‑2026 revenue of $9.8‑$10.0 M, 45‑47% above consensus, marking its first public guidance release.
likely upward pressure as investors price in the revenue beat.
The company’s revenue guidance substantially exceeds analyst expectations, which typically drives a short‑term rally.
Market effects
Positive signal for the interventional MRI device sector and related med‑tech peers.
May boost sentiment for US‑listed small‑cap biotech/med‑tech stocks.
Limited to niche medical‑device market; no broad macro effect.
Counterpoint
If the guidance proves unsustainable, the stock could face a pull‑back once actual results are released.
Key entities
- ExecutiveArun Menawat
CEO and Chairman of Profound Medical, quoted on the revenue outlook.
